The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparing, dispensing, and administering antineoplastic therapy and to the agents, commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
A randomized, comparative study of combination chemotherapies in advanced gastric cancer: 5-fluorouracil and cisplatin (FP) versus 5-fluorouracil, cisplatin, and 4'-epirubicin (FPEPIR). Kyoto Research Group for Chemotherapy of Gastric Cancer (KRGCGC). Anticancer Res.1992; 12(6B): 1983–1988.
2.
PoorterR.L., BakkerP.J., TaatC.W.. Epirubicin, cisplatin and intermittent continuous infusion of 5-fluorouracil in advanced gastric cancer: an effective regimen?Eur J Cancer.1994; 30A(9):1404.
3.
HighleyM.S., ParnisF.X., TrotterG.A.. Combination chemotherapy with epirubicin, cisplatin and 5-fluorouracil for the palliation of advanced gastric and oesophageal adenocarcinoma. Br J Surg.1994; 81(12): 1763–1765.
4.
ZaniboniA., BarniS., LabiancaR.. Epirubicin, cisplatin, and continuous infusion 5-fluorouracil is an active and safe regimen for patients with advanced gastric cancer. An Italian Group for the Study of Digestive Tract Cancer (GISCAD) report. Cancer.1995; 76(10): 1694–1699.
5.
PoorterR.L., BakkerP.J., FockensP.. Intermittent continuous infusion of 5-fluorouracil in combination with epirubicin and cisplatin in advanced gastric cancer: the importance of dose intensity. J Infus Chemother.1996; 6(2): 87–91.
6.
IçliF., CelikI., AykanF.. A randomized phase III trial of etoposide, epirubicin, and cisplatin versus 5-fluorouracil, epirubicin, and cisplatin in the treatment of patients with advanced gastric carcinoma. Turkish Oncology Group. Cancer.1998; 83(12): 2475–2480.
7.
WatersJ.S., NormanA., CunninghamD.. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer.1999; 80(1–2): 269–272.
8.
RothA., KolaricK., ZupancD.. High doses of 5-fluorouracil and epirubicin with or without cisplatin in advanced gastric cancer: a randomized study. Tumori.1999; 85(4): 234–238.
9.
AitiniE., RabbiC., MambriniA.. Epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) in locally advanced or metastatic gastric cancer: a single institution experience. Tumori.2001; 87(1): 20–24.
10.
ChoE.K., LeeW.K., LimD.Y.. Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for advanced gastric carcinoma. J Korean Med Sci.2002; 17(3): 348–352.
11.
Thuss-PatienceP.C., KretzschmarA., ReppM.. Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study. J Clin Oncol.2005; 23(3): 494–501.
12.
FindlayM., StoreyD., GebskiV.. A pilot study of preoperative and postoperative chemotherapy in patients with operable gastric cancer: Australasian Gastrointestinal Trials Group Study 9601. ANZ J Surg.2007; 77(4): 247–252.
13.
RothA.D., FazioN., StuppR.. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol.2007; 25(22): 3217–3223.
14.
LeongT., MichaelM., FooK.. Adjuvant and neoadjuvant therapy for gastric cancer using epirubicin/cisplatin/5-fluorouracil (ECF) and alternative regimens before and after chemoradiation. Br J Cancer.2003; 89(8): 1433–1438.
15.
FindlayM., CunninghamD., NormanA.. A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol.1994; 5(7): 609–616.
16.
BamiasA., HillM.E., CunninghamD.. Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for esophagogastric adenocarcinoma: response, toxicity, quality of life, and survival. Cancer.1996; 77(10): 1978–1985.
17.
WebbA., CunninghamD., ScarffeJ.H.. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol.1997; 15(1): 261–267.
18.
RossP., NicolsonM., CunninghamD.. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol.2002:20(8): 1996–2004.
19.
BamiasA., CunninghamD., NicolsonV.. Adjuvant chemotherapy for oesophagogastric cancer with epirubicin, cisplatin and infusional 5-fluorouracil (ECF): a Royal Marsden pilot study. Br J Cancer.1995; 71(3): 583–586.
20.
MelcherA.A., MortD., MaughanT.S.Epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) as neoadjuvant chemotherapy in gastro-oesophageal cancer. Br J Cancer.1996; 74(10): 1651–1654.
21.
StricklandA.H., KarapetisC.S., YipD.. Adjuvant chemotherapy for gastro-oesophageal cancer with epirubicin, cisplatin and fluorouracil: a single-centre experience. Clin Oncol (R Coll Radiol).2001; 13(1): 66.
22.
ForshawM.L., GossageJ.A., ChrystalK.. Symptomatic responses to neoadjuvant chemotherapy for carcinoma of the oesophagus and oesophagogastric junction: are they worth measuring?Clin Oncol (R Coll Radiol).2006; 18(4): 345–350.
23.
CunninghamD., AllumW.H., StenningS.P.. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med.2006; 355(1): 11–20.
24.
EllisP.A., NormanA., HillA.. Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours. Eur J Cancer.1995; 31A(10):1594–1598.
25.
MorizaneC., OkadaS., OkusakaT.. Phase II study of cisplatin, epirubicin, and continuous-infusion 5-fluorouracil for advanced biliary tract cancer. Oncology.2003; 64(4): 475–476.
26.
JangJ.W., BaeS.H., ChoiJ.Y.. A combination therapy with transarterial chemo-lipiodolization and systemic chemo-infusion for large extensive hepatocellular carcinoma invading portal vein in comparison with conservative management. Cancer Chemother Pharmacol.2007; 59(1): 9–15.
27.
TakezakoY., OkusakaT., UenoH.. Phase II study of cisplatin, epirubicin and continuous infusion of 5-fluorouracil in patients with advanced intrahepatic cholangiocellular carcinoma (ICC). Hepatogastroenterology.2008; 55(85): 1380–1384.
28.
RaoS., CunninghamD., HawkinsR.E.. Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer. Br J Cancer.2005; 92(9): 1650–1654.
29.
GarganoL., MenichettiE.T., MarcelliniM.. Epirubicin, cisplatin and continuous-infusion 5-fluorouracil (ECF regimen) in the treatment of advanced colorectal cancer. Chemotherapy.2001; 47(6): 438–443.
30.
CrawleyC., RossP., NormanA.. The Royal Marsden experience of a small bowel adenocarcinoma treated with protracted venous infusion 5-fluorouracil. Br J Cancer.1998; 78(4): 508–510.
31.
JonesA.L., SmithI.E., O'BrienM.E.. Phase II study of continuous infusion fluorouracil with epirubicin and cisplatin in patients with metastatic and locally advanced breast cancer: an active new regimen. J Clin Oncol.1994; 12(6): 1259–1265.
32.
EisenT., SmithI.E., JohnstonS.. Randomized phase II trial of infusional fluorouracil, epirubicin, and cyclophosphamide versus infusional fluorouracil, epirubicin, and cisplatin in patients with advanced breast cancer. J Clin Oncol.1998; 16(4): 1350–1357.
33.
BonnefoiH., SmithI.E., O'BrienM.E.. Phase II study of continuous infusional 5-fluorouracil with epirubicin and carboplatin (instead of cisplatin) in patients with metastatic/locally advanced breast cancer (infusional ECarboF): a very active and well-tolerated outpatient regimen. Br J Cancer.1996; 73(3): 391–396.
34.
TorrisiR., BalduzziA., GhisiniR.. Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel. Cancer Chemother Pharmacol.2008; 62(4): 667–72.
35.
SmithI.E., JonesA.L., O'BrienM.E.. Primary medical (neo-adjuvant) chemotherapy for operable breast cancer. Eur J Cancer.1993; 29A(12):1796–9. Corrected and republished from: Eur J Cancer. 1993; 29A(4):592-595.
36.
SmithI.E., WalshG., JonesA.. High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer. J Clin Oncol.1995; 13(2): 424–429.
37.
SmithI.E., A'HernR.P., CoombesG.A.. A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neo-adjuvant treatment of early breast cancer: 5 year results of the TOPIC trial. Ann Oncol.2004; 15(5): 751–758.
38.
RoccaA., PeruzzottiG., GhisiniR.. A randomized phase II trial comparing preoperative plus perioperative chemotherapy with preoperative chemotherapy in patients with locally advanced breast cancer. Anticancer Drugs.2006; 17(10): 1201–1209.
39.
RischinD., CorryJ., SmithJ.. Excellent disease control and survival in patients with advanced nasopharyngeal cancer treated with chemoradiation. J Clin Oncol.2002; 20(7): 1845–1852.
40.
MasonR.Palliation of malignant dysphagia: an alternative to surgery. Ann R Coll Surg Engl.1996; 78(5): 457–462.
41.
EvansT.R., LoftsF.J., MansiJ.L.. A phase II study of continuous-infusion 5-fluorouracil with cisplatin and epirubicin in inoperable pancreatic cancer. Br J Cancer.1996; 73(10): 1260–1264.
42.
ChaoD., von SchlippeM., HarlandS.J.A phase II study of continuous infusion 5-fluorouracil (5-FU) with epirubicin and cisplatin in metastatic, hormone-resistant prostate cancer: an active new regimen. Eur J Cancer.1997; 33(8): 1230–1233.
43.
ParnisF.X., OlverI.N., KotasekD.. Phase II study of epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) for carcinoma of unknown primary site. Ann Oncol.2000; 11(7): 883–884.
44.
NioY., TsengC.C., ShiraishiT.. A phase II study of 5-fluorouracil, cisplatin, and 4'-epirubicin in the treatment of advanced solid cancers. Am J Clin Oncol.1993; 16(2): 96–101.
45.
National Comprehensive Cancer Network clinical practice guidelines in oncology - gastric cancer. V.2.2009. National Comprehensive Cancer Network Web site. http://www.nccn.org. Accessed September 1, 2009.
46.
National Comprehensive Cancer Network clinical practice guidelines in oncology - esophageal cancer. V.1.2009. National Comprehensive Cancer Network Web site. http://www.nccn.org. Accessed September 1, 2009.
47.
HeskethP.J., KrisM.G., GrunbergS.M.. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol.1997; 15(1): 103–109.
48.
National Comprehensive Cancer Network clinical practice guidelines in oncology - antiemesis. V.3.2009. National Comprehensive Cancer Network Web site. http://www.nccn.org. Accessed September 1, 2009.
49.
KrisM.G., HeskethP.J., SomerfieldM.R.. American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006. J Clin Oncol.2006; 24(18): 2932–2947.
KrisM.G., GrallaR.J., ClarkR.A.. Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol.1985; 3: 1379–1384.
52.
GelingO., EichlerH.G.Should 5-Hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol.2005; 23(6): 1289–1294.
53.
TerreyJ.P., AaproM.S.The activity of granisetron in patients who had previously failed ondansetron antiemetic therapy. Eur J Clin Res.1996; 8: 281–288.
54.
CarmichaelJ., KeizerH.J., CupissolD., MilliezJ., ScheidelP., SchindlerA.E.Use of granisetron in patients refractory to previous treatment with antiemetics. Anticancer Drugs.1998; 9(5): 381–385.
55.
de WitR., de BoerA.C., vd LindenG.H., StoterG., SparreboomA., VerweijJ.Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer.2001; 85(8): 1099–1101.
56.
SmithI.E.A dose-finding study of granisetron, a novel antiemetic, in patients receiving cytostatic chemotherapy. The Granisetron Study Group. J Cancer Res Clin Oncol.1993; 119(6): 350–354.
57.
SoukopM.A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin. Granisetron Study Group. Support Care Cancer.1994; 2(3): 177–183.
58.
CornelisonT.L., ReedE.Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gynecol Oncol.1993; 50(2): 147–158.
59.
KintzelP.E.Anticancer drug-induced kidney disorders - incidence, prevention and management. Drug Safety.2001; 24(1): 19–38.
ZanottiK.M., MarkhamM.Prevention and management of antineoplastic-induced Hypersensitivity reactions. Drug Safety.2001; 24(10): 767–779.
62.
SmithT.J., KhatcheressianJ., LymanG.H.. 2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline. J Clin Oncol.2006; 24(19): 3187–3205.
63.
National Comprehensive Cancer Network clinical practice guidelines in oncology - myeloid growth factors. V.1.2009. National Comprehensive Cancer Network Web site. http://www.nccn.org. Accessed September 1, 2009.
64.
LarsonD.L.Treatment of tissue extravasation by antitumor agents. Cancer.1982; 49(9): 1796–1799.
65.
LarsonD.L.What is the appropriate management of tissue extravasation by antitumor agents?Plast Reconstr Surgery.1985; 75(3): 397–402.
66.
MullinS., BeckwithM.C., TylerL.S.Prevention and management of antineoplastic extravasation injury. Hosp Pharm.2000; 35(1): 57–74.
67.
MarounJ.A., AnthonyL.B., BlaisN.. Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a consensus statement by the Canadian Working Group on chemotherapy-induced diarrhea. Curr Oncol.2007; 14(1): 13–20.
68.
BensonA.B., AjaniJ.A., CatalanoR.B.. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol.2004; 22(14): 2918–2926.
69.
AronoffG.R., BennettW.M., BernsJ.S., BrierM.E., KasbekarN., MuellerB.A., PaskoD.A., SmoyerW.E.Drug Prescribing in Renal Failure.5th ed.Philadelphia, PA: American College of Physicians; 2007.
70.
KintzelP.E., DorrR.T.Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev.1995; 21(1): 33–64.
71.
DobbsN.A., TwelvesC.J., GregoryW., CruickshankaC., RichardsM.A., RubensR.D.Epirubicin in patients with liver dysfunction: development and evaluation of a novel dose modification scheme. Eur J Cancer.2003; 39(5): 580–586.
72.
FloydJ., MirzaI., Sachs, PerryM.C.Hepatotoxicity of chemotherapy. Semin Oncol.2006; 33(1): 50–67.
73.
KingP.D., PerryM.C.Hepatotoxicity of chemotherapy. Oncologist.2001; 6(2): 162–176.
